Skip to main content

Table 4 Breakpoints of 17 antibiotics

From: In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates

Antimicrobial agent

MIC breakpoints (μg/mL)

Susceptibility

Intermediate

Resistance

CLAa

 ≤ 8

16

 ≥ 32

RFBb

 ≤ 2

-

 ≥ 4

EMBc

-

-

 > 5

INHc

-

-

 > 0.2

MXFa

 ≤ 1

2

 ≥ 4

RIFb

 ≤ 1

-

 ≥ 2

SXTb

 ≤ 2/38

-

 ≥ 4/76

AMIa

 ≤ 16

32

 ≥ 64

LZDa

 ≤ 8

16

 ≥ 32

CIPb

 ≤ 1

2

 ≥ 4

STRd

 ≤ 16

32

 ≥ 64

DOXb

 ≤ 1

2–4

 ≥ 8

ETHc

-

-

 > 5

TZDe

-

-

 > 8

CFZd

 ≤ 1

2

 ≥ 4

BDQf

-

-

 > 0.25

CSd

 ≤ 16

32

 ≥ 64

  1. Notes: a, b, c denotes the breakpoints for MAC, M.kansasii, and M.tuberculosis coming from Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard–Third Edition. CLSI document M24-A3. d, e, f denotes the breakpoints coming from previous studies [29, 45, 62]
  2. Abbreviations: CLA Clarithromycin, RFB Rifabutin, EMB Ethambutol, INH Isoniazid, MXF Moxifloxacin, RIF Rifampin, SXT Trimethoprim/sulfamethoxazole, AMI Amikacin, LZD Linezolid, CIP Ciprofloxacin, STR Streptomycin, DOX Doxycycline, ETH Ethionamide, TZD Tedizolid, CFZ Clofazimine, BDQ Bedaquiline, CS Cycloserine
Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us